Meridian Bioscience

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Meridian Bioscience is an integrated life science company. The Company is engaged in developing, manufacturing, selling, and distributing clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory, and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in three segments: U.S. Diagnostics, European Diagnostics, and Life Science.

CINCINNATI, OH / ACCESSWIRE / September 1, 2021 / Meridian Bioscience, Inc. (NASDAQ:VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced its wholly owned subsidiary, Magellan Diagnostics, Inc. ("Magellan"), expanded the Class I recall of its LeadCare® II Blood Lead Test Kits, LeadCare Plus® Blood Lead Test Kits, and LeadCare Ultra® Blood Lead Test Kits (the "LeadCare Test Kits") for the detection of lead in whole blood. Magellan provides two controls in the test kits which are designed to mimic blood and are spiked with lead to specific target values with an associated acceptable range.

Meridian Bioscience, Inc.: Magellan Diagnostics, Inc. Expands Voluntary Recall of LeadCare Test Kits

Antares Pharma

These healthcare stocks have their warts, but the price is right for long-term investors.

Got $1,000? These 2 Bargain-Bin Biopharma Stocks Might Be Worth Buying

Meridian Bioscience, Inc. (VIVO) CEO John Kenny on Q3 2021 Results - Earnings Call Transcript

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of -29.03% and -13.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience (VIVO) Q3 Earnings and Revenues Miss Estimates

Shares of Meridian Bioscience (NASDAQ:VIVO) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share decreased 60.00% year over year to $0.22, which missed the estimate of $0.31.

Meridian Bioscience: Q3 Earnings Insights

CINCINNATI, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2021.

Meridian Bioscience Reports Third Quarter Fiscal 2021 Results

CINCINNATI, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the previously announced acquisition of the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. effective July 31, 2021.

Meridian Closes Acquisition of BreathTek® Business

CINCINNATI, July 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. for $20 million in cash. The transaction is expected to close in Meridian's fiscal fourth quarter.

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc.

CINCINNATI, July 14, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter fiscal 2021 financial results Friday, August 6, 2021.

Meridian Bioscience to Hold Third Quarter Fiscal 2021 Financial Results Conference Call on August 6, 2021

In the latest trading session, Meridian Bioscience (VIVO) closed at $22.05, marking a +1.61% move from the previous day.

Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know

A rapid increase in Delta variant spread in the world may be good news for Meridian's testing supply business.

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

CINCINNATI, June 28, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has re-submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company's SARS-CoV-2 molecular diagnostic test on the Revogene® platform.

Meridian Resubmits Application to FDA for Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay

CINCINNATI, June 16, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready™ RT-LAMP Mix, specifically designed for accelerating the development of ambient temperature stable reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) assays. The Lyo-Ready™ RT-LAMP Mix is formulated for rapid, robust, and sensitive detection of RNA viruses.

Meridian's New Master Mix for LAMP Assays Offers a Practical Solution for POC Molecular Detection of RNA viruses

CINCINNATI, May 27, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today participation in two upcoming investor conferences. Jack Kenny, Chief Executive Officer, will participate in a live, virtual fireside chat at the 41st Annual William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 4:20 PM ET. Jack Kenny will also pre-record a presentation for the Jefferies Virtual Healthcare Conference which will be webcast on Friday, June 4, 2021 at 2:00 PM ET.

Meridian Bioscience to Participate in the 41st Annual William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference

CINCINNATI, May 17, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct DNA qPCR Plant Mix. This unique Mix is specifically designed to develop and manufacture multiplexed highly sensitive and economical molecular field-tests in agriculture biotechnology (AgBio).

Meridian Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples

Meridian Bioscience, Inc. (VIVO) CEO John Kenny on Q2 2021 Results - Earnings Call Transcript

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 16.67% and -2.26%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience (VIVO) Beats Q2 Earnings Estimates

CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021.

Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Meridian Bioscience (VIVO) Reports Next Week: Wall Street Expects Earnings Growth

Meridian Bioscience (VIVO) closed at $20.76 in the latest trading session, marking a -1.66% move from the prior day.

Meridian Bioscience (VIVO) Dips More Than Broader Markets: What You Should Know

CINCINNATI, April 28, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready™ DNA LAMP Mix, specifically designed for accelerating the development of ambient temperature-stable loop-mediated isothermal amplification (LAMP) assays. The Lyo-Ready™ DNA LAMP Mix is formulated for rapid, robust, and sensitive DNA amplification through nucleic acid strand displacement.

Meridian Simplifies Workflows for POC Molecular Tests with a New Lyo-Ready™ LAMP Mix

Enel Americas

Fulgent Genetics

If you are screening the market for high-return investments, you may want to consider the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt (Trades, Portfolio)'s method) are topping the U.S. market.

A Trio of High-Return, Non-Cyclical Stocks for the Value Investor

CINCINNATI, April 19, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter fiscal 2021 financial results Friday, May 7, 2021.

Meridian Bioscience to Hold Second Quarter Fiscal 2021 Financial Results Conference Call on May 7, 2021

Adaptive Biotechnologies

Barnwell Industries

GenMark Diagnostics

Roche Holding AG

Meridian Bioscience Inc. (NASDAQ:VIVO) edged out GenMark Diagnostics Inc. (NASDAQ:GNMK) as the top gainer in the March GenomeWeb Index with a 25% boost in its share price compared to GenMark's 22.5% increase. At the other end of the spectrum were Adaptive Biotechnologies Corp. (NASDAQ:ADPT), whose shares plummeted 28%, Burning Rock Biotech (BRN) with a 25% decline and Quanterix Corp. (QNTX), which fell 22.8%.

GenomeWeb Index Drops 3% for 2nd Consecutive Month

Meridian Bioscience benefited from a windfall due to the Covid-19 pandemic, resulting in the growth of its Life Science segment.

News for Meridian Bioscience Stock (VIVO)